Suntinorexton

Suntinorexton
Clinical data
Drug class	Orexin OX2 receptor agonist
Identifiers
	IUPAC name N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide;
CAS Number	2274802-89-8 ;
PubChem CID	137460941;
UNII	FF2NQ35DA4;
Chemical and physical data
Formula	C23H28F2N2O4S
Molar mass	466.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O;
	InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1; Key:MQDUVMBBJZLFHF-PMACEKPBSA-N;

Suntinorexton (INNTooltip International Nonproprietary Name) is an experimental orexin receptor agonist.^[1] It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[2] It is being evaluated for the treatment of narcolepsy.^[3]

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123
^ WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.
^ Konofal E (August 2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacology, Biochemistry, and Behavior. 241: 173804. doi:10.1016/j.pbb.2024.173804. PMID 38852786.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.